The advent of high-throughput sequencing technologies has revolutionized our understanding of the genetic basis of cancer, paving the way for significant advancements in personalized medicine.  Cancer is fundamentally a disease of the genome, arising from the accumulation of somatic mutations that disrupt cellular processes like growth control and apoptosis.  Identifying these driver mutations, which confer a selective growth advantage to cancerous cells, is crucial for targeted therapy.  Next-generation sequencing allows for comprehensive profiling of tumor genomes, revealing specific mutations in oncogenes and tumor suppressor genes, as well as alterations in epigenetic modifications and copy number variations. This information informs the selection of tailored therapeutic strategies, moving beyond traditional cytotoxic chemotherapies.  For instance, patients with EGFR mutations in lung cancer respond dramatically to EGFR tyrosine kinase inhibitors, while those with BRAF mutations in melanoma benefit from BRAF inhibitors.  Furthermore, genomic profiling can predict treatment response, toxicity, and prognosis, enabling clinicians to optimize treatment plans and minimize adverse effects.  These advancements in personalized oncology continue to evolve, with ongoing research focused on expanding the repertoire of targetable mutations and developing novel therapeutic agents guided by genetic information, ultimately leading to improved cancer outcomes.